{
    "organizations": [],
    "uuid": "0aa8a47f3d123fb4b2e2daee2520e7ae00bfa338",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-shenzhen-hepalink-pharmaceutical-u/brief-shenzhen-hepalink-pharmaceutical-unit-gets-approval-for-new-drug-clinical-trial-in-australia-idUSL3N1PE21Q",
    "ord_in_thread": 0,
    "title": "BRIEF-Shenzhen Hepalink Pharmaceutical unit gets approval for new drug clinical trial in Australia",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 19 (Reuters) - Shenzhen Hepalink Pharmaceutical Co Ltd :\n* Says its controlling Shenzhen-based biotech subsidiary gets approval for new drug Ib/IIa clinical trial in Australia\n* The new drug is used for treatment of hyperlipemia\nSource text in Chinese: goo.gl/4PZG6r\nFurther company coverage: (Beijing Headline News)\n ",
    "published": "2018-01-19T13:12:00.000+02:00",
    "crawled": "2018-01-20T17:29:47.007+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "shenzhen",
        "hepalink",
        "pharmaceutical",
        "co",
        "ltd",
        "say",
        "controlling",
        "biotech",
        "subsidiary",
        "get",
        "approval",
        "new",
        "drug",
        "clinical",
        "trial",
        "australia",
        "new",
        "drug",
        "used",
        "treatment",
        "hyperlipemia",
        "source",
        "text",
        "chinese",
        "company",
        "coverage",
        "beijing",
        "headline",
        "news"
    ]
}